Latest filing published 07 Aug 2026 for AtriCure, Inc., €117k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Maggie Yuen span 2 companies, the busiest being Penumbra Inc and AtriCure, Inc. Over a trading history stretching from 16 December 2019 to 5 August 2026, the count stands at 47 filings.
No open-market purchase appears, only 12 sales worth €2.7M. Besides market trades, the filings include 32 share grants and 3 option exercises. In 2026 alone, the filings show no purchases and 2 sales.
Most recently, on 7 August 2026, the filings show an open-market sale worth €117k in AtriCure, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 28 declarations